SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review

Kavita Narang, Elizabeth Ann L. Enninga, Madugodaralalage D.S.K. Gunaratne, Eniola R. Ibirogba, Ayssa Teles A. Trad, Amro Elrefaei, Regan N. Theiler, Rodrigo Ruano, Linda M. Szymanski, Rana Chakraborty, Vesna D. Garovic

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has been associated with worse outcomes in several patient populations, including the elderly and those with chronic comorbidities. Data from previous pandemics and seasonal influenza suggest that pregnant women may be at increased risk for infection-associated morbidity and mortality. Physiologic changes in normal pregnancy and metabolic and vascular changes in high-risk pregnancies may affect the pathogenesis or exacerbate the clinical presentation of COVID-19. Specifically, SARS-CoV-2 enters the cell via the angiotensin-converting enzyme 2 (ACE2) receptor, which is upregulated in normal pregnancy. Upregulation of ACE2 mediates conversion of angiotensin II (vasoconstrictor) to angiotensin-(1-7) (vasodilator) and contributes to relatively low blood pressures, despite upregulation of other components of the renin-angiotensin-aldosterone system. As a result of higher ACE2 expression, pregnant women may be at elevated risk for complications from SARS-CoV-2 infection. Upon binding to ACE2, SARS-CoV-2 causes its downregulation, thus lowering angiotensin-(1-7) levels, which can mimic/worsen the vasoconstriction, inflammation, and pro-coagulopathic effects that occur in preeclampsia. Indeed, early reports suggest that, among other adverse outcomes, preeclampsia may be more common in pregnant women with COVID-19. Medical therapy, during pregnancy and breastfeeding, relies on medications with proven safety, but safety data are often missing for medications in the early stages of clinical trials. We summarize guidelines for medical/obstetric care and outline future directions for optimization of treatment and preventive strategies for pregnant patients with COVID-19 with the understanding that relevant data are limited and rapidly changing.

Original languageEnglish (US)
Pages (from-to)1750-1765
Number of pages16
JournalMayo Clinic proceedings
Issue number8
StatePublished - Aug 2020

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review'. Together they form a unique fingerprint.

Cite this